Moss, 12 February 2025
Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, today announced its results for the fourth quarter 2024.
Highlights
- Record sales of NOK 42.6 million in 4Q24, up 14% vs 4Q23 (13% organic growth). Revenue of NOK 152.1 million for the full year 2024, up 13% vs 2023 (13% organic growth).
- Sales of fCAL® turbo increased 34% in 4Q24 compared to 4Q23, and 42% in 2024 vs 2023.
- Strong US sales growth of 101% in 4Q24 and 39% for the full year 2024 vs 2023.
- Improvement of gross margin to 56%, up from 43% in 4Q23.
- Significant EBITDA improvement to NOK 8.1 million in 4Q24 versus NOK -1.0 million in 4Q23. EBITDA of NOK 24.7 million in 2024 versus NOK 3.3 million in 2023.
- Net profit of NOK 45.3 million including capitalisation of tax loss carried forward of NOK 25.2 million.
- The board proposes a dividend of NOK 0.40 per share due to a solid cash position and sound underlying earnings with current growth opportunities fully financed.
- The NT-proBNP assay development progressed as planned and further studies indicated comparable performance to existing market leading assays. Collaborations with clinical partners have been further strengthened, with contracts finalized to secure access to additional clinical cohorts.
GDASA interim report 4Q 2024
GDASA 4Q 24 presentation
Webcast
The company will present the results today at 10.00 am, followed by a Q&A session. The presentation will be held as a live webcast on the company's website: https://www.gentian.com//investor-relation/presentations The webcast will also be available on the company website after the presentation.
IR contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.
This stock exchange announcement was published by Ole Sørlie, Business Controller at Gentian Diagnostics ASA, on 12 February 2025 at 08:00 CET.
About Gentian
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within immunoassays, specifically for infections, inflammation, kidney failure and congestive heart failure. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian Diagnostics is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.